Skip to main content
. Author manuscript; available in PMC: 2015 Jun 7.
Published in final edited form as: Cancer. 2010 Oct 1;116(19):4580–4589. doi: 10.1002/cncr.25319

Figure 1.

Figure 1

Comparison of modified fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) versus standard hyper-CVAD with regard to (Top) survival and (Bottom) complete response duration.